Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  IGI LABORIGI       

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 93,7 M
EBIT 2017 11,2 M
Net income 2017 -1,98 M
Debt 2017 93,1 M
Yield 2017 -
Sales 2018 141 M
EBIT 2018 26,5 M
Net income 2018 13,8 M
Debt 2018 99,9 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 34,28
EV / Sales2017 5,52x
EV / Sales2018 3,73x
Capitalization 424 M
More Financials
Company
Teligent, Inc. develops, manufactures and markets topical formulations.The company sells generic topical pharmaceutical products under IGI label.It also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter and cosmetic markets.The company's products... 
Sector
Pharmaceuticals
Calendar
05/02Earnings Release
More about the company
Surperformance© ratings of IGI LABORIGI
Trading Rating : Investor Rating :
More Ratings
Latest news on IGI LABORIGI
03/22 TELIGENT, INC. : To Present At Oppenheimer 27th Annual Healthcare Conference On ..
03/17 TELIGENT, INC. (NASDAQ : TLGT) Files An 8-K Results of Operations and Financial ..
03/17 TELIGENT : Results of Operations and Financial Condition, Financial Statements a..
03/16 TELIGENT : Announces FDA Approval Of Clobetasol Propionate Gel, 0.05%
03/15 TELIGENT : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
03/13 TELIGENT, INC. : To Present At 29th Annual ROTH Conference On March 13, 2017
03/10 TELIGENT : Announces FDA Approval Of Clobetasol Propionate Gel, 0.05%
03/08 TELIGENT, INC. : Announces FDA Approval Of Clobetasol Propionate Gel, 0.05%
03/07 TELIGENT : reports 4Q loss
03/07 TELIGENT, INC. : Results of Operations and Financial Condition, Financial Statem..
More news
Sector news : Pharmaceuticals - NEC
02:38p FDA, Mylan silence on generic Advair may be good news for GSK
01:43p British business navigates rocky path to Brexit
09:52a ConvaTec's majority investors raise $1.2 billion via stake sale
03/28DJSenator McCaskill Begins Probe of Prescription Opioid Marketing -- 2nd Update
03/28DJSHIRE : Files 8K - Other Events
More sector news : Pharmaceuticals - NEC
Advertisement
Chart IGI LABORIGI
Duration : Period :
IGI LABORIGI Technical Analysis Chart | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 10,5 $
Spread / Average Target 32%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jason Grenfell-Gardner President, Chief Executive Officer & Director
James Charles Gale Chairman
Jenniffer L. Collins CFO, Secretary & Head-Investor Relations
Stephen Richardson Chief Scientific Officer
Nadya Lawrence Senior Vice President-Technical Services
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IGI LABORIGI89.51%424
JOHNSON & JOHNSON9.19%340 651
ROCHE HOLDING LTD.8.73%221 256
PFIZER INC.5.17%203 427
NOVARTIS AG-0.34%196 620
MERCK & CO., INC.7.59%173 904
More Results